Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093053 | 0.87 | KMT2A (0.57) | STAT3MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL6094269 | 0.80 | KMT2A (0.55) | STAT3MEN1KMT2AADRB2ALDH1A1 | |
| SCHEMBL30403102 | 0.78 | CA12 (0.44) | MEN1KMT2AALDH1A1TSHRATM | |
| SCHEMBL3348404 | 0.76 | STAT3 (0.65) | STAT3KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL14918321 | 0.76 | HDAC6 (0.49) | — | |
| SCHEMBL29501713 | 0.75 | KDM4E (0.47) | MEN1KMT2AALDH1A1KDM4ECYP19A1 | |
| SCHEMBL3351884 | 0.75 | STAT3 (0.59) | STAT3KMT2AALDH1A1ATMKDM4E | |
| SCHEMBL5192260 | 0.74 | STAT3 (0.57) | STAT3KMT2AALDH1A1ATMKDM4E | |
| SCHEMBL9995716 | 0.74 | PPARG (0.41) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL29378424 | 0.74 | ACHE (0.50) | ALDH1A1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | STAT3 3899/4885MEN1 2183/4885KMT2A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.